AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
AstraZeneca is conducting a Phase III clinical study titled ‘A Phase III, Randomised, Open-label, Sponsor-blinded, Multicentre Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma.’ The study aims to evaluate the efficacy and safety of rilvegostomig combined with bevacizumab, with or without tremelimumab, compared to atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma (HCC).
The study tests three interventions: a combination of rilvegostomig, bevacizumab, and tremelimumab; rilvegostomig and bevacizumab; and atezolizumab with bevacizumab. These drugs are administered as intravenous therapies, targeting advanced HCC in patients unsuitable for curative or locoregional treatments.
This interventional study follows a randomized, parallel assignment model with single masking for outcomes assessors. Its primary purpose is treatment, focusing on the safety and efficacy of the drug combinations.
The study began on May 6, 2025, with its primary completion date yet to be determined. The last update was submitted on July 1, 2025. These dates are crucial as they mark the study’s progress and potential timelines for results.
The update on this study could influence AstraZeneca’s stock performance and investor sentiment, as positive outcomes may enhance the company’s competitive position in the oncology market. Investors should watch for developments, as successful results could impact the broader pharmaceutical landscape.
The study is currently recruiting, and further details are available on the ClinicalTrials portal.